Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series

Journal of Neurology

Volumn 263, Issue 1, 2016, Pages 25-29

  Azzopardi, Laura ^a   Cox, Amanda L ^b   McCarthy, Claire L ^b   Jones, Joanne L ^a   Coles, Alasdair J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Alemtuzumab; Multiple sclerosis; Neuroimmunology; Neuromyelitis optica

Indexed keywords

ALEMTUZUMAB; MITOXANTRONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CERVICAL SPINAL CORD INJURY; CHILD; DISABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMITED MOBILITY; MULTIPLE CYCLE TREATMENT; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; UNITED KINGDOM; VISUAL IMPAIRMENT; WHITE MATTER LESION; FEMALE; NEUROMYELITIS OPTICA; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; NEUROMYELITIS OPTICA; TREATMENT FAILURE;

EID: 84955743052     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7925-y     Document Type: Article

References (14)

1. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35(11):3332–3342. doi:10.1002/eji.200535075
2. Jones JL, Thompson SAJ, Loh P, Davies JL, Tuohy OC, Curry AJ, Azzopardi L, Hill-Cawthorne G, Fahey MT, Compston A, Coles AJ (2013) Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci. doi:10.1073/pnas.1313654110
3. Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83(3):298–304. doi:10.1136/jnnp-2011-300826
4. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14):1069–1078. doi:10.1212/WNL.0b013e31824e8ee7
5. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828
6. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839. doi:10.1016/s0140-6736(12)61768-1
7. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112. doi:10.1016/s0140-6736(04)17551-x
8. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol (Zurich, Switzerland) 24(1):83–97. doi:10.1111/bpa.12099
9. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489. doi:10.1212/01.wnl.0000216139.44259.74
10. Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, De Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon J, Tenembaum S, Traboulsee A, Waters P, Wellik K, Weinshenker B (2014) Revised diagnostic criteria for neuromyelitis optica spectrum disorders (S63.001). Neurology 82(10 Suppl):S63.001
11. Wang KC, Lin KH, Lee TC, Lee CL, Chen SY, Chen SJ, Chin LT, Tsai CP (2014) Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions. PLoS One 9(6):e98192. doi:10.1371/journal.pone.0098192
12. Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP, Paul F, Aktas O (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239–245. doi:10.1001/archneurol.2011.216
13. Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP (2013) Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70(3):390–393. doi:10.1001/jamaneurol.2013.668
14. Gelfand JM, Cotter J, Klingman J, Huang EJ, Cree BA (2014) Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm 1(3):e34. doi:10.1212/nxi.0000000000000034